Platform Technology Development for Biologically Targeted Dosimetry and Radiotherapy

Frederic Zenhausern, PhD, MBA
Published: Monday, Oct 12, 2015
Frederic Zenhausern, PhD, MBA

Frederic Zenhausern, PhD, MBA

The ability to obtain high-quality radiobiological information about the interactions between tumor and healthy tissue, when using ionizing radiations, would contribute to the development of more effective and personalized radiotherapy treatments. It would also benefit both medical research and clinical radio-oncology communities involved in technology development of molecular assays, such as genomic-based biodosimetry or predictive proteomic assay for lateeffects toxicity. Today, biomedical imaging is also allowing noninvasive molecular phenotyping and providing molecular- specific predictive and response biomarkers to clinical therapies. The spectrum of approaches is broad, and our team at the University of Arizona’s Center for Applied NanoBioscience and Medicine (the Center) has since developed expertise in creating new platform technologies integrating genomic and proteomic biomarker signatures into assay platforms for molecular-based biodosimetry, or for assessing toxicity and tissue radio-sensitivity in view of gaining knowledge in the biological mechanisms that could guide precise therapies.

Our aim is to operate a Center of Excellence dedicated to translational research and to the convergence of multidisciplinary technological skills of national or international significance in the fields of nano-biotechnology and radiobiological sciences. Since 2005, the Center has innovated multiple molecular profiling platforms for biodosimetry through its projects portfolio sponsored by federal agencies (eg, Department of Health and Human Services/Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases); more recently, by international consortia (eg, RadioGenomic Consortium), that contributed to the emerging field of radiomics (ie, genomics, metabolomics, and imaging textural analysis) providing molecular biomarkers of tissue specific responses to radiations. The Center has also entered a memorandum of understanding agreement with the National Centre of Oncological Hadrontherapy in Italy allowing it access to facilities infrastructure for conducting comparative studies of photon, proton and carbon ion treatments. These resources provide an operational framework structured in 3 major research themes: (1) integrated microsystems for automating biospecimen workflow processing and molecular assay chemistries, (2) in vitro radiobiology models, and (3) preclinical trials on patients.

Radiomics Assays Platforms for Personalizing Radiotherapies

Radiomics Assays Platforms for Personalizing Radiotherapies

Over the last several years, the Center has developed microfluidic platforms and instrumentation for integrating the entire workflow processing of biological fluid samples onto lab-on-chip devices. The Lab-on-a-Chip technology has arisen out of the desire to incorporate multiple lab processes within a single platform. This is done for a variety of reasons: to optimize speed, reliability, reagent usage, cost reduction, contamination, and automation, among many others. In particular, rapid DNA analysis from buccal swabs, saliva, and a small volume of blood collected from a fingerstick have been implemented for multiplex genomic profiling of short tandem repeats bio-signatures used in tissue or human identification.1

Similarly, white blood cell separation from the whole blood is important for genomic or proteomic analysis of the cells for clinical diagnostics; and for medical countermeasures in a disaster response. In the case of a radiological event, such as a dirty bomb attack or a clinical radiotherapy accident, individuals may be exposed to different doses of radiation that shall trigger different medical treatments.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication